secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2026-02-04T23:59:59+00:00
Accession:  0001104659-26-010065
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus enters Phase 1b combo trial with Janssen for tagmokitug in mCRPC
------------------------------------------------------------------------

- Clinical supply agreement with Janssen to evaluate tagmokitug (anti-CCR8) plus pasritamig in mCRPC Phase 1b.
- Coherus sponsors trial; Janssen supplies pasritamig. Both retain full commercial rights to their compounds.
- Tagmokitug is an investigational cytolytic monoclonal antibody targeting CCR8; study to start in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000110465926010065/0001104659-26-010065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000110465926010065/chrs-20260204x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-010065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer